Summary:
- Researchers have discovered a new potential treatment for cystic fibrosis patients who are resistant to current therapies.
- The study found that a combination of two existing drugs, lumacaftor and ivacaftor, can help restore the function of the defective CFTR protein that causes cystic fibrosis.
- This discovery offers hope for improving the quality of life and long-term outcomes for cystic fibrosis patients who do not respond well to standard treatments.